Osteosarcomas (OS) are the most common malignant bone tumor. The disease originates within the fastest growing areas of the long bones of children and young adults, where the histologic hallmark of OS is malignant bone formation (osteoid). Improvements in treatments have proven difficult to date with metastatic OS remaining a bleak prognosis routinely leading to lung metastases to ultimately cause death.

Larkspur Biosciences Inc. recently published findings uncovering a role for B cells in antitumor immunity, and highlighting TIM-1 as a targetable checkpoint protein central to B-cell antitumor activity.

Researchers from Westlake Therapeutics (Hangzhou) Co. Ltd. have presented the discovery and preclinical evaluation of a novel erythrocyte-anti-PD-1 antibody conjugate, WTX-212, being developed for the treatment of cancer.

Back-to-back papers in the June 22, 2023, issue of Nature have identified separate molecular mechanisms underlying sex-specific cancer outcomes. Researchers from The University of Texas MD Anderson Cancer Center showed that increased expression of the epigenetic enzyme KDM5D, which is located on the Y chromosome, contributed to cancer progression in KRAS-mutated tumors. In the same issue of Nature, a team from Cedars-Sinai reported new insights into the consequences of losing the entire Y chromosome.

Replay Holdings LLC and The University of Texas MD Anderson Cancer Center have announced that the FDA has cleared the IND application for NY-ESO-1 TCR/IL-15 NK, an engineered T-cell receptor natural killer (TCR-NK) cell therapy for advanced synovial sarcoma and myxoid/round cell liposarcoma.

TG Immunopharma Co. Ltd. has announced clearance by the FDA for a clinical trial of TGI-6, a bispecific antibody targeting unique tumor-associated antigens (TAA) and CD3 molecules simultaneously, for solid tumors.

Researchers from Innate Pharma SA recently presented preclinical data for IPH-6501, a novel CD20-targeting tetraspecific antibody-based natural killer (NK)-cell engager therapeutic being developed for the treatment of patients with B-cell non-Hodgkin lymphoma (B-NHL).

Along with preliminary first-in-human data, investigators from F-star Therapeutics Inc. recently presented preclinical results for the tetravalent bispecific antibody FS-222, which targets PD-L1 and CD137 and is being developed for the treatment of advanced treatment-refractory solid tumors.

Alentis Therapeutics AG has received FDA clearance of the company’s IND application for ALE.C04, a first-in-class monoclonal antibody developed to specifically target exposed Claudin-1 (CLDN1) on cancer cells.